David graduated from Washington University in St. Louis in 2011 with a B.S. in Biomedical Engineering. He joined the Medical Scientist Training Program (MD/PhD) at the University of Michigan and has completed two years of medical school. As a medical student, David conducted clinical research on outcomes of endovascular treatment for intracranial aneurysms. In 2013, David joined the Graduate Program in Immunology and began his graduate work in the laboratory of Dr. Benjamin Segal. His current work investigates the role of arginase-expressing myeloid cells in autoimmune demyelinating disease.
Multiple sclerosis (MS) is the leading non-traumatic cause of neurological disability among young adults. MS is believed to be initiated by myelin-reactive CD4+ T cells which infiltrate the central nervous system (CNS) and promote further recruitment of immune cells, including monocytes/macrophages and dendritic cells. Little is known about the cellular composition and properties of these myeloid cell populations in the CNS during different stages of disease. Using an animal model of MS, current studies are investigating the functional role of CNS myeloid populations marked by iNOS or arginase-1 expression in the pathophysiology of autoimmune demyelinating disease.
- 2017 - Rackham Predoctoral Fellowship Award
- 2016 - Monte V. Hobbs Student Award
- 2015 - Science X-Prize, Curriculum Development Award
- 2014 - Rackham Experimental Grant, Rackham Graduate School
- 2014 - Second Place, Taubman Institute Symposium Poster Competition